Clinical

The first drugs for nonalcoholic steatohepatitis (NASH) won't be approved until 2019 at the earliest, but with 16 million Americans affected and another 6 million to 10 million at high risk, the market could be expensive and it's worth keeping an eye on, said Aimee Tharaldson, PharmD, senior clinical consultant for emerging therapeutics at Express Scripts.

A study evaluating a patient-reported outcomes measure tool in patients who had undergone colorectal surgery recommends using the tool for preoperative counseling prior to surgery.

Eli Lilly and Company has announced that abemaciclib improved progression-free survival (PFS) when combined with an aromatase inhibitor (AI), compared with AI alone, in patients with breast cancer.

The University of Connecticut has initiated recruitment for a phase I trial to test the safety and efficacy of OncoImmunome, a personalized vaccine designed to prevent relapse in patients diagnosed with Stage III or IV ovarian cancer.

At this year’s meeting, themed Fueling the Cancer Moonshot, attendees will gain a better understanding of strategies for success within the community oncology realm.

The approval of the Paxman Scalp Cooling System follows a randomized clinical trial, whose results were published in JAMA following an interim analysis.

Despite the wide variety of rare diseases out there, children and families living with rare disease have one thing in common: they experience diagnostic delays. A new study in Orphanet Journal of Rare Diseases described experiences of seeking and receiving a diagnosis of a rare disease and access to healthcare.

JAMA study highlights need for considering patient preferences when choosing between treatment options for prostate cancer.

Richard J. Willke, PhD, chief science officer of ISPOR, previews the discussions at the ISPOR 22nd Annual International Meeting, which will be held May 20-24 in Boston, Massachusetts, including topics on the future of health policy in the United States and social networking interventions.

The approval comes following phase 2 results of 119 patients who participated in the IMvigor210 study.

The European Respiratory Society and the American Thoracic Society have conducted a comprehensive review of evidence of managing exacerbations of chronic obstructive pulmonary disease in order to create a guideline of clinical recommendations.

A new collaboration between the Duke Clinical Research Institute, Duke University’s MURDOCK Study, and Boehringer Ingelheim Pharmaceuticals Inc will try to better understand how chronic obstructive pulmonary disease progresses in the real world.